BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22889108)

  • 1. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
    Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
    BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.
    Molloy TJ; Bosma AJ; Baumbusch LO; Synnestvedt M; Borgen E; Russnes HG; Schlichting E; van't Veer LJ; Naume B
    Breast Cancer Res; 2011 Jun; 13(3):R61. PubMed ID: 21672237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis.
    Bilani N; Elson L; Liang H; Elimimian EB; Arteta-Bulos R; Nahleh Z
    Technol Cancer Res Treat; 2020; 19():1533033820980107. PubMed ID: 33287661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
    Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S
    Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy.
    Walter VP; Taran FA; Wallwiener M; Hahn M; Brucker SY; Hartkopf AD
    Arch Gynecol Obstet; 2018 Mar; 297(3):785-790. PubMed ID: 29380106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.
    Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
    Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
    Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer.
    Wiedswang G; Borgen E; Schirmer C; Kåresen R; Kvalheim G; Nesland JM; Naume B
    Int J Cancer; 2006 Apr; 118(8):2013-9. PubMed ID: 16287086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
    Takeyama H; Shimada T; Kinoshita S; Uchida K
    Ann Surg Oncol; 2017 May; 24(5):1227-1233. PubMed ID: 27909824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity.
    Gröbe A; Blessmann M; Hanken H; Friedrich RE; Schön G; Wikner J; Effenberger KE; Kluwe L; Heiland M; Pantel K; Riethdorf S
    Clin Cancer Res; 2014 Jan; 20(2):425-33. PubMed ID: 24218516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.